Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Development Officer

Chief Commercial Officer

Chief Medical Officer

EVP, Chief Accounting Officer

See Remarks

President, CEO, and Chairman

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase III SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, a drug that is in Phase II clinical trial for the treatment and prophylaxis of dengue; and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, and Zika virus, as well as Ruzasvir, an investigational NS5A inhibitor for the treatment of chronic HCV infection. It also develops a co-formulated, oral, pan-genotypic fixed dose combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virous (HCV); It has a license agreement with Merck & Co, Inc. development, manufacture, and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral ...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-02-01	Premium	sold	Premium	Premium	Premium	Chief Development Officer
2024-02-01	Premium	sold	Premium	Premium	Premium	Chief Commercial Officer
2024-02-01	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2024-02-01	Premium	sold	Premium	Premium	Premium	EVP, Chief Accounting Officer
2024-02-01	Premium	sold	Premium	Premium	Premium	See Remarks
2024-02-01	Premium	sold	Premium	Premium	Premium	President, CEO, and Chairman
2024-01-31	Premium	acquired	Premium	Premium	Premium	Chief Development Officer
2024-01-31	Premium	acquired	Premium	Premium	Premium	Chief Commercial Officer
2024-01-31	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2024-01-31	Premium	acquired	Premium	Premium	Premium	EVP, Chief Accounting Officer
2024-01-31	Premium	acquired	Premium	Premium	Premium	See Remarks
2024-01-31	Premium	acquired	Premium	Premium	Premium	President, CEO, and Chairman
2022-11-14	Premium	sold	Premium	Premium	Premium	-
2022-11-11	Premium	sold	Premium	Premium	Premium	-
2021-12-20	Premium	bought	Premium	Premium	Premium	-
2020-11-03	Premium	bought	Premium	Premium	Premium	-
2020-11-03	Premium	acquired	Premium	Premium	Premium	-
2020-11-03	Premium	acquired	Premium	Premium	Premium	Chief Commercial Officer
2020-11-03	Premium	acquired	Premium	Premium	Premium	-
2020-11-03	Premium	acquired	Premium	Premium	Premium	-
2020-11-03	Premium	bought	Premium	Premium	Premium	-
2020-11-03	Premium	bought	Premium	Premium	Premium	-
2020-11-03	Premium	acquired	Premium	Premium	Premium	-
2020-11-03	Premium	acquired	Premium	Premium	Premium	-
2020-11-03	Premium	acquired	Premium	Premium	Premium	See Remarks

AVIR - Atea Pharmaceuticals Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for AVIR